The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty

Sung-Woo KIM; Young-Bae KIM; Jeong-Eun LEE; Na-Ri KIM; Weon-Kyung LEE; Jae-Kyun KU; Eun-Jeong KIM; Sun-Hee JUNG; Woo-Yeong CHUNG.
Annals of Pediatric Endocrinology & Metabolism ; : 95-101, 2017.
Artículo en Inglés | WPRIM | ID: wpr-49254

Documentos relacionados

  1. Girls with idiopathic central precocious puberty did not display substatial changes in body mass index after treatment with gonadotropin-releasing hormone analogues.
  2. Diagnosis and management of precocious sexual maturation: an updated review.
  3. [Value of single-phase gonadotropin-releasing hormone stimulation test in diagnosis of central precocious puberty in girls with different levels of body mass index].
  4. Basal gonadotropin levels combine with pelvic ultrasound and pituitary volume: a machine learning diagnostic model of idiopathic central precocious puberty.
  5. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis.
  6. Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.
  7. Effect of gonadotropin-releasing hormone analogue treatment in improving final adult height of children with central precocious puberty or early and fast puberty: a Meta analysis.
  8. Development and validation of a model for predicting the adult height of girls with idiopathic central precocious puberty.
  9. Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?
  10. The value of urinary gonadotropins in the diagnosis of central precocious puberty: a meta-analysis.